2020 American Transplant Congress
Evaluation of an Intervention to Reduce Underdosing of Valganciclovir for Primary Prophylaxis of Cytomegalovirus Infection in Donor Seropositive/Recipient Seronegative Kidney and Liver Transplant Recipients
*Purpose: Valganciclovir (VCV) prophylaxis is used to prevent primary cytomegalovirus (CMV) infection in CMV donor seropositive/recipient seronegative (D+/R-) solid organ transplant recipients (SOT). We examined…2020 American Transplant Congress
Valganciclovir Prophylaxis is Not Associated with Polyomavirus Viremia after Renal Transplantation
1Albany Medical Center, Albany, NY, 2Surgery, Albany Medical Center, Albany, NY
*Purpose: Recent studies have implicated prophylactic valganciclovir (VGC) therapy after renal transplantation to be associated with an increased rate of BK polyomavirus viremia and nephropathy.…2019 American Transplant Congress
Ganciclovir Based Prophylaxis against Cytomegalovirus Viremia in Pediatric Renal Transplant Patients: A Systematic Review and Meta-Analysis
*Purpose: Cytomegalovirus (CMV) disease continues to stand as a significant threat to the longevity of renal transplants in children. More pediatric recipients are CMV negative…2019 American Transplant Congress
Lower Rates of Epstein-Barr Virus Viremia and Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients Who Received Valganciclovir Prophylaxis
*Purpose: Antiviral prophylaxis to prevent post-transplant lymphoproliferative disease (PTLD) remains controversial, but some data suggest that valganciclovir or ganciclovir use in Epstein-Barr virus (EBV) high-risk…2019 American Transplant Congress
Letermovir For The Treatment And Secondary Prophylaxis Of Drug Resistant CMV In Solid Organ Transplant Recipients
*Purpose: Although only approved for primary prophylaxis of CMV among allogeneic stem cell transplant recipients, there is great interest in the use of letermovir (LET)…2019 American Transplant Congress
De-Novo Letermovir Resistant Mutations in Cytomegalovirus-Infected Tissues of Solid Organs Transplant Recipients
*Purpose: Letermovir, cytomegalovirus (CMV) DNA-terminase complex (UL51, UL56, and UL89) inhibitor, revealed the efficient prophylactic effect against CMV infection including disease and DNAemia with low-grade…2019 American Transplant Congress
Real World Data Support International Consenus Guidelines on Management of CMV after Kidney Transplantation
Oslo University Hospital - Rikshospitalet, Oslo, Norway
*Purpose: Cytomegalovirus (CMV) naïve kidney transplant recipients (R-) transplanted with an organ from a CMV positive donor (D+) are at high risk for CMV disease.…2018 American Transplant Congress
An Individualized Strategy Using Virus and Immune-Based Markers to Prevent Cytomegalovirus Disease after Face Transplantation
Introduction: There is limited data on CMV prevention after face transplantation. We report an individualized approach using prophylaxis followed by surveillance and preemptive therapy guided…2018 American Transplant Congress
Recovery of Wild-Type Genotype after Documented Ganciclovir-Resistance in Transplant Recipients with Recurrent CMV Viremia
Purpose: Ganciclovir-resistant cytomegalovirus (GR-CMV) is serious complication after transplantation. Recurrence after primary GR-CMV infection is common, with literature defined rates of approximately 20-30%. It is…2018 American Transplant Congress
Multidisciplinary Approach to Prevention of Cytomegalovirus (CMV) Complications in Kidney and Liver Transplant Recipients
Background: CMV infection can be prevented in most SOT recipients providing that a prevention protocol is followed. We discovered that our center's protocol, which includes…
American Transplant Congress abstracts